What this study is
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis.
Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included.
Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder.
Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time.
Study details
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Primary Immune Deficiency
- Enrolling
- 5,000 people
- Starts
- 2007-02-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 1 Month – 100 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients known to have or suspected of having an inherited immune cell homeostasis, programmed cell death susceptibility syndrome, lymphocyte developmental block, or defective immune cell effector functions will be eligible for enrollment. We will enroll
- Patients with suspected disease if the investigator agrees that there is a high index of suspicion. Blood relatives of enrolled patients will be eligible for enrollment. There will be no limit as to age, sex, race, or disability.
You can't join if
- Severely debilitated health status or poor venous access may preclude obtaining adequate specimens for analysis. The minimum weight for infants on this protocol is 3 kg because of the limits of maximal acceptable blood draw volumes and minimum requirement for core laboratory tests would exceed the acceptable volume.
- Co-enrollment guidelines: Participants may be co-enrolled in other studies including NIH protocols 05-I-0213, 93-I-0063 and 17-I-0122. Participants should inform the investigator of participation in other research studies.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (8)
8 openNational Institutes of Health Clinical Center
Bethesda, Maryland, United States
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contact800-411-1222 ext. TTY dial 711ccopr@nih.gov
RecruitingUniversity of Michigan
Ann Arbor, Michigan, United States
- Kelly Walkovich, M.D. · Contact215-590-2204kwalkovi@med.umich.edu
Recruiting
6 sites outside the US
Ankara Medical University
Ankara, Turkey (Türkiye)
- Aydan Ikinciogullari, MD · ContactNot Listed ext. 903123191440aydan@mac.com
Recruiting- Recruiting
- Recruiting
Marmara University
Istanbul, Turkey (Türkiye)
- Ahmet Ozen, M.D. · Contact+90216625454ahmetozen_md@yahoo.com
RecruitingSureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye)
RecruitingNecemttin Erbakan University
Konya, Turkey (Türkiye)
- Sevgi Keles, M.D. · ContactNot Listedsevgi_keles@yahoo.com
Recruiting
Study team
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Study ID 060015
Principal investigator
Helen C Su, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.